Literature DB >> 25380238

Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain.

Kristy M Heppner1, Melissa Kirigiti, Anna Secher, Sarah Juel Paulsen, Rikley Buckingham, Charles Pyke, Lotte B Knudsen, Niels Vrang, Kevin L Grove.   

Abstract

Glucagon-like peptide-1 (GLP-1) is released from endocrine L-cells lining the gut in response to food ingestion. However, GLP-1 is also produced in the nucleus of the solitary tract, where it acts as an anorectic neurotransmitter and key regulator of many autonomic and neuroendocrine functions. The expression and projections of GLP-1-producing neurons is highly conserved between rodent and primate brain, although a few key differences have been identified. The GLP-1 receptor (GLP-1R) has been mapped in the rodent brain, but no studies have described the distribution of GLP-1Rs in the nonhuman primate central nervous system. Here, we characterized the distribution of GLP-1R mRNA and protein in the adult macaque brain using in situ hybridization, radioligand receptor autoradiography, and immunohistochemistry with a primate specific GLP-1R antibody. Immunohistochemistry demonstrated that the GLP-1R is localized to cell bodies and fiber terminals in a very selective distribution throughout the brain. Consistent with the functional role of the GLP-1R system, we find the highest concentration of GLP-1R-immunoreactivity present in select hypothalamic and brainstem regions that regulate feeding, including the paraventricular and arcuate hypothalamic nuclei, as well as the area postrema, nucleus of the solitary tract, and dorsal motor nucleus of the vagus. Together, our data demonstrate that GLP-1R distribution is highly conserved between rodent and primate, although a few key species differences were identified, including the amygdala, where GLP-1R expression is much higher in primate than in rodent.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25380238      PMCID: PMC4272390          DOI: 10.1210/en.2014-1675

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  86 in total

1.  The glucagon-like peptide-1 receptor--or not?

Authors:  Charles Pyke; Lotte Bjerre Knudsen
Journal:  Endocrinology       Date:  2013-01       Impact factor: 4.736

2.  Body composition, dietary intake, and energy expenditure after laparoscopic Roux-en-Y gastric bypass and laparoscopic vertical banded gastroplasty: a randomized clinical trial.

Authors:  Torsten Olbers; Sofia Björkman; Ak Lindroos; Almantas Maleckas; Lars Lönn; Lars Sjöström; Hans Lönroth
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

3.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

Authors:  M Tang-Christensen; P J Larsen; R Göke; A Fink-Jensen; D S Jessop; M Møller; S P Sheikh
Journal:  Am J Physiol       Date:  1996-10

4.  GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.

Authors:  Minsuk Kim; Mathew J Platt; Tadao Shibasaki; Susan E Quaggin; Peter H Backx; Susumu Seino; Jeremy A Simpson; Daniel J Drucker
Journal:  Nat Med       Date:  2013-03-31       Impact factor: 53.440

5.  Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans.

Authors:  Adil E Bharucha; Nisha Charkoudian; Christopher N Andrews; Michael Camilleri; David Sletten; Alan R Zinsmeister; Phillip A Low
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-07-02       Impact factor: 3.619

6.  Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.

Authors:  Kana Inoue; Norikazu Maeda; Susumu Kashine; Yuya Fujishima; Junji Kozawa; Aki Hiuge-Shimizu; Kohei Okita; Akihisa Imagawa; Tohru Funahashi; Iichiro Shimomura
Journal:  Cardiovasc Diabetol       Date:  2011-12-01       Impact factor: 9.951

Review 7.  Physiology and emerging biochemistry of the glucagon-like peptide-1 receptor.

Authors:  Francis S Willard; Kyle W Sloop
Journal:  Exp Diabetes Res       Date:  2012-05-14

8.  Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.

Authors:  J van Can; B Sloth; C B Jensen; A Flint; E E Blaak; W H M Saris
Journal:  Int J Obes (Lond)       Date:  2013-09-03       Impact factor: 5.095

9.  Incretin-based therapies: focus on effects beyond glycemic control alone.

Authors:  Jaime A Davidson
Journal:  Diabetes Ther       Date:  2013-09-21       Impact factor: 2.945

10.  Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake.

Authors:  Darleen A Sandoval; Didier Bagnol; Stephen C Woods; David A D'Alessio; Randy J Seeley
Journal:  Diabetes       Date:  2008-05-16       Impact factor: 9.461

View more
  64 in total

Review 1.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

2.  Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.

Authors:  Elliot J Glotfelty; Thomas Delgado; Luis B Tovar-Y-Romo; Yu Luo; Barry Hoffer; Lars Olson; Tobias Karlsson; Mark P Mattson; Brandon Harvey; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  ACS Pharmacol Transl Sci       Date:  2019-02-11

3.  Pharmacokinetics and efficacy of PT302, a sustained-release Exenatide formulation, in a murine model of mild traumatic brain injury.

Authors:  Miaad Bader; Yazhou Li; Daniela Lecca; Vardit Rubovitch; David Tweedie; Elliot Glotfelty; Lital Rachmany; Hee Kyung Kim; Ho-Il Choi; Barry J Hoffer; Chaim G Pick; Nigel H Greig; Dong Seok Kim
Journal:  Neurobiol Dis       Date:  2018-11-22       Impact factor: 5.996

Review 4.  The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review.

Authors:  Amanda Brunchmann; Morgane Thomsen; Anders Fink-Jensen
Journal:  Physiol Behav       Date:  2019-04-01

Review 5.  PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation.

Authors:  Stefan Trapp; Simon C Cork
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-08-19       Impact factor: 3.619

6.  DREADDing proglucagon neurons: a fresh look at metabolic regulation by the brain.

Authors:  Jonathan E Campbell; David A D'Alessio
Journal:  J Clin Invest       Date:  2017-02-20       Impact factor: 14.808

Review 7.  Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.

Authors:  Ambika Shandilya; Sidharth Mehan
Journal:  Neurol Sci       Date:  2021-05-21       Impact factor: 3.307

8.  Intranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice.

Authors:  Huinan Zhang; Jingru Meng; Shimeng Zhou; Yunhan Liu; Di Qu; Ling Wang; Xubo Li; Ning Wang; Xiaoxing Luo; Xue Ma
Journal:  AAPS J       Date:  2015-12-21       Impact factor: 4.009

9.  Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.

Authors:  Therese S Salameh; Elizabeth M Rhea; Konrad Talbot; William A Banks
Journal:  Biochem Pharmacol       Date:  2020-08-02       Impact factor: 5.858

Review 10.  GLP-1 and weight loss: unraveling the diverse neural circuitry.

Authors:  Scott E Kanoski; Matthew R Hayes; Karolina P Skibicka
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-03-30       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.